ADAGIO THERAPEUTICS Funding & Investors
Adagio Therapeutics is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1, and additional potentially emergent coronaviruses. They believe that antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs and can be used as both therapeutic and durable prophylactic treatments. Their candidates are engineered using best-in-industry antibody discovery capabilities and are designed to maximize potency and duration of effect. Their portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape.
adagiotx.comTotal Amount Raised: $466,000,000
ADAGIO THERAPEUTICS Funding Rounds
Series C
$336,000,000
Series C Investors
Ra Capital ManagementPremjiInvestArrowMark PartnersForesite CapitalRedmile GroupOmega FundsPolaris PartnersFidelity InvestmentsGVMithril Capital ManagementAdimabPopulation Health PartnersOrbiMedFederated InvestorsSeries B
$80,000,000
Series B Investors
GVMithril Capital ManagementFidelity InvestmentsOrbiMedPolaris PartnersOmega FundsPopulation Health PartnersSeries A
$50,000,000
Series A Investors
Mithril Capital ManagementPolaris PartnersAdimabOrbiMedFidelity InvestmentsGVM28 Capital
Funding info provided by Diffbot.